The estimated Net Worth of Krishnan Nandabalan is at least 14.8 百万$ dollars as of 6 April 2023. Dr Nandabalan owns over 60,000 units of BioXcel Therapeutics Inc stock worth over 33,000$ and over the last 6 years he sold BTAI stock worth over 14,590,298$. In addition, he makes 150,000$ as Chief Digital Officer ?& Director at BioXcel Therapeutics Inc.
Dr has made over 5 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of BTAI stock worth 24,600$ on 6 April 2023.
The largest trade he's ever made was selling 473,250 units of BioXcel Therapeutics Inc stock on 25 June 2021 worth over 14,590,298$. On average, Dr trades about 81,781 units every 199 days since 2018. As of 6 April 2023 he still owns at least 60,000 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Dr Nandabalan stock trades at the bottom of the page.
Dr. Krishnan Nandabalan is the Chief Digital Officer ?& Director at BioXcel Therapeutics Inc.
As the Chief Digital Officer ?& Director of BioXcel Therapeutics Inc, the total compensation of Dr Nandabalan at BioXcel Therapeutics Inc is 150,000$. There are 7 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of 1,968,930$.
Dr Nandabalan is 58, he's been the Chief Digital Officer ?& Director of BioXcel Therapeutics Inc since . There are 7 older and 7 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Krishnan's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over 63,244,788$ worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth 321,105$ . The most active insiders traders include Vimal Bio Xcel Holdings, In...、Vimal Mehta、Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 29,814$. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth 413$.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: